Da nilotinib og dets metabolitter ikke udskilles via nyrerne, forventes et fald i total- clearance ikke hos patienter med nyreinsufficiens.
Since nilotinib and its metabolites are not renally excreted, a decrease in total body clearance is not anticipated in patients with renal impairment.